Hemobiological properties of gliclazide

摘要: Non-insulin-dependent diabetes mellitus (NIDDM) is associated with an increased risk of macro- and microvascular degenerative complications. Gliclazide a second generation sulfonylurea that widely used in the treatment type II mellitus. Its hypoglycemic activity well documented. In addition to its metabolic effects, gliclazide has beneficial effects on hemobiological abnormalities NIDDM. These are mediated by azabicyclo-octyl ring grafted aulfonylurea core. Numerous studies have demonstrated reduces platelet hyperadhesion hyperaggregability. actions been extensively confirmed diabetic patients over periods up 3 years. With regard functions, several groups significant reduction serum intraplatelet beta thromboglobulin thromboxane B2. animal models, in-vitro in-vivo stimulates endothelial prostacyclin synthesis. The compound thromboxane/prostacyclin balance recently after 3-month period. Concerning fibrinolysis, restores low plasminogen normal NIDDM previously treated first-generation sulfonyl-ureas. increases fibrinolytic potential increasing cell tissue activator pre-kallikrein activity. More recent suggest may fibrin network structure, rendering more amenable fibrinolysis. Finally, it shown potent free-radical-scavenging vitro. This property vivo reactivity oxidative stress related these patients.(ABSTRACT TRUNCATED AT 250 WORDS)